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A bs tr ac t
Background
Transcatheter aortic-valve replacement (TAVR) is the recommended therapy for pa-
tients with severe aortic stenosis who are not suitable candidates for surgery. The 
outcomes beyond 1 year in such patients are not known.
Methods
We randomly assigned patients to transfemoral TAVR or to standard therapy (which 
often included balloon aortic valvuloplasty). Data on 2-year outcomes were analyzed.
Results
A total of 358 patients underwent randomization at 21 centers. The rates of death at 
2 years were 43.3% in the TAVR group and 68.0% in the standard-therapy group 
(P<0.001), and the corresponding rates of cardiac death were 31.0% and 62.4% 
(P<0.001). The survival advantage associated with TAVR that was seen at 1 year re-
mained significant among patients who survived beyond the first year (hazard ratio, 
0.58; 95% confidence interval [CI], 0.36 to 0.92; P = 0.02 with the use of the log-rank 
test). The rate of stroke was higher after TAVR than with standard therapy (13.8% vs. 
5.5%, P = 0.01), owing, in the first 30 days, to the occurrence of more ischemic 
events in the TAVR group (6.7% vs. 1.7%, P = 0.02) and, beyond 30 days, to the occur-
rence of more hemorrhagic strokes in the TAVR group (2.2% vs. 0.6%, P = 0.16). At 
2 years, the rate of rehospitalization was 35.0% in the TAVR group and 72.5% in the 
standard-therapy group (P<0.001). TAVR, as compared with standard therapy, was 
also associated with improved functional status (P<0.001). The data suggest that the 
mortality benefit after TAVR may be limited to patients who do not have extensive 
coexisting conditions. Echocardiographic analysis showed a sustained increase in 
aortic-valve area and a decrease in aortic-valve gradient, with no worsening of para-
valvular aortic regurgitation.
Conclusions
Among appropriately selected patients with severe aortic stenosis who were not 
suitable candidates for surgery, TAVR reduced the rates of death and hospitaliza-
tion, with a decrease in symptoms and an improvement in valve hemodynamics that 
were sustained at 2 years of follow-up. The presence of extensive coexisting condi-
tions may attenuate the survival benefit of TAVR. (Funded by Edwards Lifesciences; 
ClinicalTrials.gov number, NCT00530894.)
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Symptomatic aortic stenosis, if left untreated, is characterized by a high risk of death.1-6 In the randomized Placement of 
Aortic Transcatheter Valves (PARTNER) trial, trans-
catheter aortic-valve replacement (TAVR), as com-
pared with standard therapy, in patients who were 
not considered to be suitable candidates for sur-
gery, decreased the rate of death at 1 year, reduced 
cardiac symptoms, and improved the hemodynam-
ic performance of the valve.2 Longer-term outcomes 
are essential to guide clinical practice decisions 
in this elderly patient population, in which many of 
the patients have multiple coexisting conditions. 
Moreover, there is a paucity of long-term data on 
the performance of the valve, and most of the data 
that are available include echocardiograms that 
have not been analyzed at an independent core 
laboratory.7-10 The objective of this analysis was 
to report 2-year findings from the PARTNER trial 
and to perform subgroup analyses in order to gain 
a better understanding of the effect of coexisting 
conditions on survival.
Me thods
Study Design and Patients
The PARTNER trial was a multicenter, randomized 
study involving patients with severe aortic stenosis 
(aortic-valve area of <0.8 cm2) and with cardiac 
symptoms (New York Heart Association [NYHA] 
functional class II or higher), who were consid-
ered not to be suitable candidates for surgery be-
cause of either clinical or anatomical factors.2 
The entry criteria were stringent, requiring at-
testation by two cardiac surgeons and an inter-
ventional cardiologist that the patient was not a 
suitable candidate for surgery (as indicated by a 
≥50% probability that the patient would either 
die or have serious irreversible complications after 
conventional surgical aortic-valve replacement). 
Written informed consent was obtained from all 
the patients in the study.
Full details of the inclusion and exclusion cri-
teria have been reported previously.2 Patients were 
randomly assigned, in a 1:1 ratio, to TAVR or 
standard therapy, which included balloon aortic 
valvuloplasty, at the discretion of the treating 
physicians.
Study Oversight
The trial was designed by the sponsor (Edwards 
Lifesciences) and members of the executive com-
mittee. The sponsor participated in the selection 
and management of the sites and the collection and 
monitoring of the data. The first author, the co-
principal academic investigators, and the executive 
committee had unrestricted access to the data af-
ter the database was locked, made the decision to 
submit the manuscript for publication, prepared 
all drafts of the manuscript, and attest to the in-
tegrity of the trial and the completeness and ac-
curacy of the reported data, as well as to the fidel-
ity of the study to the trial protocol. The protocol, 
including the statistical analysis plan, is available 
with the full text of this article at NEJM.org.
All serious adverse events were adjudicated by 
an independent clinical events committee. All data 
were analyzed by a biostatistician who was paid 
by the sponsor and by an academic biostatistician. 
An independent core laboratory analyzed all echo-
cardiograms.
Procedure
The SAPIEN heart-valve system (Edwards Life-
sciences), which was used in this study, consisted 
of a balloon-expandable, stainless-steel stent frame 
housing a tri-leaflet bovine pericardial valve with-
in a deflectable delivery catheter. The system was 
inserted into the common femoral artery under 
aseptic conditions, with the use of both trans-
esophageal and fluoroscopic guidance, while the 
patient was under general anesthesia.2
End Points
The prespecified primary end point of the 
PARTNER trial was all-cause mortality, over the 
duration of the trial. The key end points for this 
analysis were the 2-year rates of death from any 
cause, death from cardiac causes, stroke, and re-
peat hospitalization; NYHA functional class; num-
ber of days alive and out of the hospital; and 
echocardiographic assessments of aortic-valve gra-
dients, aortic-valve area, and paravalvular regur-
gitation. We used the Society of Thoracic Sur-
geons (STS) risk score (which ranges from 0% to 
100%, with higher scores indicating greater sur-
gical risk) as a measure of coexisting conditions 
and stratified mortality according to STS risk cat-
egories (<5%, 5 to 14.9%, and ≥15%).
Statistical Analysis
We estimated the sample size on the basis of the 
primary end point (all-cause mortality).2 The anal-
yses of clinical outcomes were performed on data 
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from the intention-to-treat population, which in-
cluded all patients who underwent randomization, 
regardless of the treatment received. Echocardio-
graphic analyses were performed according to the 
treatment received. Categorical variables were com-
pared with the use of Fisher’s exact test. Continu-
ous variables, which are presented as means with 
standard deviations, were compared with the use 
of Student’s t-test. Survival curves for time-to-
event variables were constructed on the basis of all 
available follow-up data with the use of Kaplan–
Meier estimates and were compared by means of 
the log-rank test. The last date a patient was alive 
was derived from the database, with the use of in-
formation on office visits, telephone calls, dates 
on which adverse events were reported, and the 
actual reported date of death. A two-sided alpha 
level of 0.05 was used for superiority testing. All 
patients were followed for at least 2 years after 
randomization. A generalized linear model was 
used to calculate risk ratios in prespecified sub-
groups and to test for interactions. To assess the 
effect of balloon aortic valvuloplasty on mortality 
in the standard-therapy group, we performed time-
dependent covariate analyses. After completion 
of 1 year of follow-up, patients in the standard-
therapy group were permitted to cross over to the 
TAVR group. Data from the small minority of the 
patients in the standard-therapy group who crossed 
over were censored at the time of crossover. All 
statistical analyses were performed with the use 
of SAS software, version 9.2 (SAS Institute).
R esult s
Patients and Enrollment
Patients were enrolled at 21 centers worldwide 
(17 in the United States) between May 11, 2007, and 
March 16, 2009. A total of 358 patients with severe 
aortic stenosis who were considered to be unsuit-
able candidates for surgery were assigned to either 
TAVR or standard therapy (Fig. 1 in the Supple-
mentary Appendix, available at NEJM.org).
The patients enrolled in the study were elderly 
(mean age, 83 years) and had severe cardiac symp-
toms (93% had NYHA class III or IV symptoms). 
The baseline characteristics of the patients in the 
two groups have been described previously2 and 
were generally well balanced between the groups 
(Table 3 in the Supplementary Appendix), with 
the exception of the presence of chronic obstruc-
tive pulmonary disease (COPD) and the presence 
of atrial fibrillation, for which the rates were 
higher in the standard-therapy group than in the 
TAVR group, and the presence of extensively cal-
cified (porcelain) aorta, for which the rate was 
higher in the TAVR group. Although the overall 
risk of surgery was high (STS score, 11.6±6.0%), 
many patients had a low STS score but had spe-
cific anatomical or clinical factors that contributed 
to the surgeons’ assessment that they were not 
suitable candidates for surgery. These factors in-
cluded a porcelain aorta (15.1%), chest-wall de-
formity or deleterious effects of prior chest-wall 
irradiation (13.1%), COPD requiring supplemental 
oxygen (23.5%), and frailty, as defined according to 
prespecified criteria (23.1%).
Two-Year Clinical Outcomes
Mortality
At 2 years (Fig. 1), the rate of death from any 
cause was 68.0% among patients in the standard-
therapy group, as compared with 43.3% among 
patients in the TAVR group (P<0.001). The out-
comes were essentially unchanged when data from 
patients who had crossed over from standard 
therapy to TAVR were not censored (67.6% in the 
standard-therapy group vs. 43.3% in the TAVR 
group, P<0.001). The rate of death from cardiac 
causes was also significantly higher in the stan-
dard-therapy group than in the TAVR group (62.4% 
vs. 31.0%, P<0.001). The differences in survival re-
mained significant after the first year: when the 
two groups were compared with the use of the 
proportional-hazards algorithm, conditional on 
survival to 1 year, the rate of death in year 2 was 
18.2% in the TAVR group as compared with 35.1% 
in the standard-therapy group (hazard ratio with 
TAVR, 0.58; 95% confidence interval [CI], 0.36 to 
0.92; P = 0.02 with the use of the log-rank test). 
In a similar analysis, the rate of cardiac death in 
year 2 was 13.2% in the TAVR group and 32.1% 
in the standard-therapy group (hazard ratio, 0.48; 
95% CI, 0.29 to 0.81; P = 0.004 with the use of the 
log-rank test).
A total of 20 of the 58 eligible patients who 
were alive at the time crossover was permitted 
(11 of whom crossed over between year 1 and year 
2) were treated with TAVR, with the procedure 
performed an average of 699±166 days (range, 
462 to 979) after the beginning of the study. The 
1-year mortality among patients who crossed over 
to TAVR was 10%, as compared with 21% among 
patients who were eligible but did not cross over. 
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A large percentage of patients in the standard-
therapy group (82.3%) underwent balloon aortic 
valvuloplasty. Patients who underwent balloon 
aortic valvuloplasty, as compared with those who 
did not undergo that procedure, appeared to have 
favorable outcomes, at least for the first 6 months 
after random assignment to standard therapy (Fig. 
2 in the Supplementary Appendix). However, a 
time-dependent covariate analysis revealed no sig-
nificant difference in the outcome according to 
whether patients underwent balloon aortic valvu-
loplasty (hazard ratio with balloon aortic valvulo-
plasty, 1.17; 95% CI, 0.75 to 1.83; P = 0.48).
Stratification of 2-year mortality according to 
STS score (<5%, 5 to 14.9%, or ≥15%) revealed a 
significant association between the outcomes of 
TAVR and the STS score (Fig. 2), with the sur-
vival benefit of TAVR diminishing with a higher 
STS score (P = 0.01 with the use of the log-rank 
test); however, there was no significant associa-
tion between the STS score and the poor out-
comes of standard therapy (P = 0.67 with the use 
of the log-rank test). In a multivariable propor-
tional-hazards model for the predictors of death 
at 2 years among patients randomly assigned to 
TAVR, the only significant factors were body-mass 
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Figure 1. Time-to-Event Analyses of Key End Points during 2 Years of Follow-up.
Panel A shows the rate of death from any cause, Panel B the rate of death from cardiac causes, Panel C the rate of rehospitalization, and 
Panel D the rate of death or stroke. Event rates were calculated with the use of Kaplan–Meier methods and were compared with the use 
of the log-rank test. Deaths from unknown causes were assumed to be deaths from cardiac causes. TAVR denotes transcatheter aortic-
valve replacement.
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index (hazard ratio per unit increase, 0.95; 95% CI, 
0.91 to 0.98; P = 0.005), prior stroke (hazard ratio, 
2.99; 95% CI, 1.19 to 7.51; P = 0.01), and COPD 
requiring supplemental oxygen (hazard ratio, 1.69; 
95% CI, 1.05 to 2.73; P = 0.03).
Functional Status
Among survivors at 2 years of follow-up, 83.1% 
in the TAVR cohort, as compared with 42.5% in 
the standard-therapy cohort, were asymptomatic 
or had mild symptoms (NYHA class I or II symp-
toms) (P<0.001) (Fig. 3 in the Supplementary Ap-
pendix). The rate of repeat hospitalization for car-
diac reasons was also lower after TAVR than with 
standard therapy (35.0% vs. 72.5%, P<0.001). At 
2 years, the median number of days alive and out 
of the hospital was considerably higher after TAVR 
than with standard therapy (699 days [interquar-
tile range, 201 to 720] vs. 355 days [interquartile 
range, 116 to 712], P<0.001).
Adverse Events
The rate of stroke was higher in the TAVR group 
than in the standard-therapy group both at 1 year 
(11.2% vs. 5.5%, P = 0.06) and at 2 years (13.8 vs. 
5.5%, P = 0.01) (Fig. 4 in the Supplementary Appen-
dix). The excess strokes in the TAVR group in the 
first 30 days were attributable to a greater num-
ber of ischemic strokes in that group: there were 
1 hemorrhagic and 12 ischemic strokes in the 
TAVR group, as compared with 0 hemorrhagic 
and 3 ischemic strokes in the standard-therapy 
group (P = 0.01). Beyond 30 days and up to 2 years, 
the excess of strokes was attributable to hemor-
rhagic events: there were 4 hemorrhagic and 
5 ische mic strokes in the TAVR group, as com-
pared with 1 hemorrhagic and 4 ischemic strokes 
in the standard-therapy group. Despite an increase 
in the rate of stroke, the composite end point at 
2 years of the rate of death or stroke was consid-
erably lower in the TAVR group than in the stan-
dard-therapy group (46.1% vs. 68.0%, P<0.001).
The results of other clinical end points are 
shown in Table 1. Between year 1 and year 2, the 
frequencies of clinically important complications 
(including myocardial infarction, major bleeding, 
renal failure, endocarditis, and the need for new 
pacemakers) were similar in the TAVR and stan-
dard-therapy groups.
Echocardiographic Findings
Echocardiographic analyses showed that the early 
hemodynamic benefits of TAVR11 were sustained 
at 2 years (Table 2). Although there was trace or 
mild paravalvular regurgitation in most of the pa-
tients who underwent TAVR, moderate-to-severe 
paravalvular aortic regurgitation was present in 
only 10% of the patients. When both central and 
paravalvular regurgitation were considered in an 
evaluation of the total volume load, the TAVR group 
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Figure 2. Two-Year Mortality, Stratified According to the Society of Thoracic Surgeons (STS) Risk Score.
Stratification according to STS categories (<5%, 5 to 14.9%, and ≥15%, on a scale of 0% to 100%, with higher scores 
indicating greater surgical risk) revealed a significant association with 2-year mortality.
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and the standard-therapy group had similar de-
grees of total aortic regurgitation at both 1 year 
and 2 years, owing to the higher prevalence and 
severity of valvular regurgitation among patients 
in the standard-therapy group. Among the 61 pa-
tients in the TAVR group for whom the results of 
baseline, year 1, and year 2 echocardiographic 
studies were available, paravalvular aortic regur-
gitation improved in 42.6%, did not change in 
41.0%, and worsened in 16.4%. None of the pa-
tients in the TAVR group had aortic regurgitation 
that worsened to a moderate-to-severe level during 
the follow-up period. Stratification of 2-year mor-
tality according to the degree of post-procedural 
paravalvular aortic regurgitation revealed a non-
significant trend toward higher cardiac mortality 
among patients with moderate-to-severe paraval-
vular aortic regurgitation than among those with 
none or only mild paravalvular aortic regurgitation 
(36.7% vs. 27.0%) (Fig. 5 in the Supplementary 
Appendix). There was also a trend toward higher 
all-cause mortality at 1 year associated with mod-
erate or severe paravalvular aortic regurgitation, 
but this difference disappeared by 2 years.
Discussion
In this 2-year analysis of the PARTNER trial in-
volving patients with severe aortic stenosis who 
were considered, according to expert surgical opin-
ion, not to be suitable candidates for surgery, we 
found that TAVR was associated with the following: 
a substantial, sustained, and incremental decrease 
in mortality, with an inverse relationship between 
the magnitude of the survival benefit and the num-
ber and severity of baseline coexisting conditions; 
a sustained improvement in quality-of-life mea-
sures, including NYHA class, the rate of repeat hos-
pitalizations, and the number of days alive and out 
of the hospital; an increased frequency of early 
ische mic strokes (≤30 days) but little change in the 
rate of late ischemic strokes (>30 days); and a sus-
Table 1. Outcomes at 1 and 2 Years in the Intention-to-Treat Population.*
Outcome 1 Year 2 Years
TAVR
(N = 179)
Standard 
Therapy
(N = 179) P Value
TAVR
(N = 179)
Standard 
Therapy
(N = 179) P Value
All-cause mortality — no. (%) 55 (30.7) 89 (50.7) <0.001 77 (43.3) 117 (68.0) <0.001
Stroke — no. (%) 19 (11.2) 8 (5.5) 0.06 22 (13.8) 8 (5.5) 0.01
Rehospitalization — no. (%) 43 (27.0) 79 (53.9) <0.001 53 (35.0) 95 (72.5) <0.001
Death or rehospitalization — no. (%) 79 (44.1) 126 (71.6) <0.001 101 (56.7) 153 (87.9) <0.001
Death or stroke — no. (%) 63 (35.2) 90 (51.3) 0.002 82 (46.1) 117 (68.0) <0.001
Cardiac death — no. (%) 35 (20.5) 75 (44.6) <0.001 50 (31.0) 100 (62.4) <0.001
NYHA class III or IV — no./total no. (%) 28/118 (23.7) 48/79 (60.8) <0.001 16/95 (16.8) 23/40 (57.5) <0.001
Myocardial infarction — no. (%) 1 (0.8) 1 (0.7) 0.91 2 (1.6) 2 (2.5) 0.69
Creatinine >3 mg/dl — no. (%) 2 (1.1) 5 (2.8) 0.45 2 (1.1) 5 (2.8) 0.45
Renal failure — no. (%)† 4 (2.3) 7 (4.7) 0.26 5 (3.2) 9 (7.6) 0.15
Major bleeding — no. (%) 42 (24.2) 21 (14.9) 0.04 48 (28.9) 25 (20.1) 0.09
Balloon aortic valvuloplasty — no. (%) 2 (1.1) 138 (82.3) <0.001 4 (2.8) 140 (85.3) <0.001
Aortic-valve replacement — no. (%) 0 10 (7.6) 0.002 1 (0.9) 11 (8.9) 0.005
Endocarditis — no. (%) 2 (1.4) 1 (0.8) 0.62 3 (2.3) 1 (0.8) 0.32
New pacemaker — no. (%) 8 (4.7) 14 (8.6) 0.15 10 (6.4) 14 (8.6) 0.47
* Percentages shown are Kaplan–Meier estimates, and P values are point-in-time analyses, with the exception of the percentages for creatinine 
>3 mg/dl (265 μmol/liter) and for New York Heart Association (NYHA) class III or IV, which are straight frequencies, with P values calculat-
ed with the use of Fisher’s exact test. All events in this table were adjudicated by an independent clinical events committee. Disparities with 
values in our previous report2 are due to updated data, based on new reports. TAVR denotes transcatheter aortic-valve replacement.
† Renal failure was defined by the need for dialysis for any length of time.
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tained improvement in the hemodynamic perfor-
mance of the valve, with no significant deteriora-
tion over time.
The 2-year mortality among patients in the 
standard-therapy group was striking (68%); half 
the patients who had been alive at 1 year died 
between year 1 and year 2, confirming that the 
prognosis of symptomatic aortic stenosis is very 
poor when valve replacement is not performed. 
It is most likely that this very high mortality is a 
result not only of untreated aortic stenosis but also 
of multiple coexisting conditions in this elderly 
patient population.12-14 TAVR was clearly supe-
rior to standard therapy in reducing all-cause and 
cardiac mortality; the number of patients needed 
to prevent any death and the number needed to 
prevent a cardiac death in the first 2 years were 
4.0 and 3.2, respectively. In a comparison of pa-
tients in the two groups who were alive after 1 year, 
the subsequent mortality at 2 years was 18.2% in 
the TAVR group, as compared with 35.1% in the 
standard-therapy group (hazard ratio, 0.58; 95% 
CI, 0.36 to 0.92; P = 0.02 with the use of the log-
rank test), which is similar to the data at 1 year 
Table 2. Echocardiographic Outcomes in the As-Treated Population.*
Outcome
Before  
Procedure
(N = 164)
30 Days after  
Procedure
(N = 145)
2 Years after  
Procedure
(N = 67) P Value
Peak gradient — mm Hg 0.80
Median† 71.5 18.6 18.7
Interquartile range 55.1–88.4 14.4–23.8 14.9–25.7
Mean gradient — mm Hg 0.59
Median† 42.7 9.3 9.7
Interquartile range 32.5–52.4 7.1–12.3 7.7–13.3
Aortic-valve area — cm2‡ 0.89
Median† 0.62 1.50 1.53
Interquartile range 0.52–0.76 1.19–1.80 1.28–1.85
Ejection fraction — % 0.69
Median 56.1 60.0 59.4
Interquartile range 46.8–61.6 55.0–65.0 54.6–60.8
Paravalvular aortic insufficiency — no./total no. (%) 0.001
None NA 22/144 (15.3) 23/67 (34.3)
Trace 29/144 (20.1) 21/67 (31.3)
Mild 75/144 (52.1) 20/67(29.9)
Moderate 17/144 (11.8) 3/67 (4.5)
Severe 1/144 (0.7) 0
Transvalvular aortic insufficiency — no./total no. (%) 0.75
None 20/164 (12.2) 47/144 (32.6) 19/67 (28.4)
Trace 35/164 (21.3) 56/144 (38.9) 33/67 (49.3)
Mild 75/164 (45.7) 40/144 (27.8) 12/67 (17.9)
Moderate 30/164 (18.3) 1/144 (0.7) 3/67 (4.5)
Severe 4/164 (2.4) 0 0
* Total numbers at the three time points are the numbers of patients for whom data on ejection fraction were available at 
each of those time points. Data for peak gradient and for mean gradient were available for 162 patients before the pro-
cedure, 143 patients 30 days after the procedure, and 65 patients 2 years after the procedure; the corresponding num-
bers for aortic-valve area were 158, 137, and 65. The P values are for the difference between 30 days and 2 years. NA 
denotes not applicable.
† P<0.001 for the difference between preprocedural and 30-day values.
‡ The aortic-valve area was calculated with the use of the continuity equation for effective orifice area.
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(hazard ratio, 0.57; 95% CI, 0.44 to 0.75; P <0.001 
with the use of the log-rank test). Hence, the con-
tinued divergence between the treatment groups in 
mortality at year 2 is significant. The findings for 
cardiac mortality were similar.
Although the magnitude of the reduction in 
mortality seen after TAVR is striking and unusual 
for any cardiovascular therapy, there remained a 
sobering 43% absolute mortality among patients in 
the TAVR group at 2 years. Therefore, it would be 
worthwhile to try to identify an at-risk population 
that would derive little or no long-term benefit 
from TAVR owing to irreversible coexisting con-
ditions or other factors. In a subgroup analysis 
of mortality outcomes according to surgical risk 
(with the use of the STS score), the mortality 
benefit with TAVR decreased with increasing STS 
score (Fig. 2). In contrast, patients in the standard-
therapy group had a consistently poor prognosis 
irrespective of the STS risk stratum. Perhaps some 
patients with very high STS scores should be 
viewed as having such severe coexisting conditions 
that TAVR therapy may be a futile exercise. On the 
other hand, patients with low STS risk scores 
(<5%) who are not considered to be suitable candi-
dates for surgery, owing largely to anatomical fac-
tors (Fig. 6 in the Supplementary Appendix), had 
the most pronounced mortality reduction with 
TAVR. Although no definite recommendations 
can be made about an absolute STS cutoff value 
until larger patient cohorts are studied, treating 
physicians should be mindful of the number and 
severity of coexisting conditions in their patients.
TAVR was also associated with an improvement 
in quality-of-life measures, including a sustained 
reduction in cardiac symptoms and fewer repeat 
hospitalizations, extending into the second year of 
follow-up. The median number of days alive and 
out of the hospital was almost twice as high in the 
TAVR group as in the standard-therapy group. This 
has substantial implications not only for quality of 
life, which has been noted by others to improve 
after TAVR,15-19 but also for the cumulative cost of 
medical treatment associated with rehospitaliza-
tion, and lends further support to the cost-effec-
tiveness of TAVR as reported thus far.20
Stroke is a disturbing complication of TAVR; 
after 2 years, the frequency of stroke was higher by 
a factor of 2 with TAVR as compared with stan-
dard therapy. This difference appeared to be driven 
predominantly by embolic ischemic events in the 
periprocedural period, as shown in other stud-
ies.21-23 Between 30 days and 2 years after TAVR, 
the rate of stroke was still higher in the TAVR 
group than in the standard-therapy group (2.8% 
vs. 5.0%) (Fig. 4 in the Supplementary Appendix), 
but the excess was driven primarily by hemor-
rhagic events. These findings do not support a 
continued risk of device-related embolic events 
beyond the first month. Cerebrovascular events 
in this high-risk patient population are the result 
of a complex interaction of many factors, includ-
ing the presence of atherosclerotic aortic and ca-
rotid disease, atrial fibrillation,24 traumatic head 
injuries in the elderly (Table 2 in the Supplemen-
tary Appendix), and concomitant anticoagulation 
and antiplatelet therapy.25 A reduction in the di-
ameter of the device, the use of distal protection 
devices,26,27 and better standardization of anti-
platelet and anticoagulation therapy28 may be 
helpful in reducing the incidence of early strokes. 
Late strokes may represent a constant hazard in 
this high-risk elderly population.
Echocardiographic analyses revealed excellent 
valve hemodynamics that remained durable over 
the course of 2 years, with no evidence of valve 
migration, leaflet thickening, or calcification. 
These data on performance of the valves 2 years 
after TAVR are reassuring because all the echo-
cardiograms were analyzed at an independent core 
laboratory. A nonsignificant trend toward higher 
cardiac mortality, but not all-cause mortality, 
among patients with moderate-to-severe aortic 
regurgitation persisted at 2 years. This finding 
differs from results among high-risk patients who 
are candidates for surgery, in whom moderate-to-
severe paravalvular aortic regurgitation is a sig-
nificant predictor of 2-year mortality,29 as shown 
previously.7,29-31 The heavy burden of coexisting 
conditions in our cohort of patients, who were not 
suitable candidates for surgery, may have compet-
ed with or masked the adverse effects of paraval-
vular aortic regurgitation.
In summary, in this randomized trial compar-
ing TAVR with standard therapy in patients with 
severe aortic stenosis who were not suitable can-
didates for surgery, TAVR reduced the rates of 
death and of hospitalization, with an improvement 
in valve hemodynamics and a reduction in symp-
toms that were sustained for at least 2 years. 
These results establish TAVR as the standard of 
care for symptomatic patients with aortic stenosis 
who do not have reasonable surgical alternatives. 
The ultimate value of TAVR in such patients will 
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depend on several factors: a further reduction in 
the risk of TAVR-associated complications, espe-
cially early stroke; the demonstration of sustained 
hemodynamic performance of the bioprosthetic 
valve; and the careful selection of patients who are 
not candidates for surgery and who do not have 
extensive coexisting conditions that might over-
whelm the benefits of TAVR and render the in-
tervention futile.
Supported by Edwards Lifesciences.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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